Total Funding
30
9
Total FundingGrant raised
Growth Score
-2 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
40380
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Lisa Danzig: Chief Medical OfficerPast Role: PaxVax, Chief Medical Officer- Yuki Shirato: Angel InvestorPast Role: Narō, Co-Founder & Advisor
About the Company
Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing
therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
